Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery

Table 2 Operative data of patients with reference to PCC administration

	Overall series				Propensity score–matched pairs
	No PCC (n = 680)	PCC (n = 291)	p Value	Pre-match SD	No PCC (n = 225)	PCC (n = 225)	p Value	Post-match SD
Type of surgery			0.009				0.901
Isolated CABG	173 (25.4)	47 (16.2)		0.228	39 (17.3)	36 (16.0)		0.035
Isolated valve surgery	226 (33.2)	113 (38.8)		0.117	92 (40.9)	88 (39.1)		0.037
Valve surgery + CABG	154 (22.6)	64 (22.0)		0.014	47 (20.9)	53 (23.6)		0.065
Aortic surgery	127 (18.7)	67 (23.0)		0.106	47 (20.9)	48 (21.3)		0.01
CPB time, min	152 ± 64	148 ± 64	0.234	0.001	150 ± 65	152 ± 68	0.734	0.001
ACC time, min	111 ± 51	106 ± 49	0.157	0.002	104 ± 46	109 ± 50	0.410	0.002
Nadir Hct during CPB, %	22.9 ± 3.9	23.9 ± 3.6	<0.0001	0.071	23.4 ± 4.3	23.7 ± 3.7	0.305	0.019

ACC aortic cross-clamp, CABG coronary artery bypass graft, CPB cardiopulmonary bypass, Hct haematocrit, PCC prothrombin complex concentrates, SD standard deviation
Continuous values are reported as mean and standard deviation; nominal variables are reported as counts and (percentages)

ISSN: 1364-8535